Cargando…
416. Poor clinical outcomes of COVID-19 patients receiving rituximab during the Omicron era
BACKGROUND: Rituximab (RTX), a widely used anti-CD20 monoclonal antibody, has been suggested as a risk factor for poor outcomes of coronavirus disease 2019 (COVID-19). However, it remains largely unknown whether COVID-19 outcomes remain worse in patients receiving RTX compared to those not being tre...
Autores principales: | Lee, Chan Mi, Kang, Chang Kyung, Jo, Hyeon Jae, Choe, Pyoeng Gyun, Kim, Nam Joong, Park, Wan Beom, Oh, Myoung-don |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678911/ http://dx.doi.org/10.1093/ofid/ofad500.486 |
Ejemplares similares
-
How We Have Treated Severe to Critically Ill Patients With Coronavirus Disease 2019 in Korea
por: Park, Do Hyeon, et al.
Publicado: (2022) -
Clinical Impact of Empirical Antibiotic Therapy in Patients With Coronavirus Disease 2019 Requiring Oxygen Therapy
por: Park, Do Hyeon, et al.
Publicado: (2022) -
Sudden Deaths of Neonates Receiving Intravenous Infusion of Lipid Emulsion Contaminated with Citrobacter freundii
por: Bae, Ji Yun, et al.
Publicado: (2018) -
Effect of Wearing Personal Protective Equipment (PPE) for COVID-19 Treatment on Blood Culture Contamination: Implication for Optimal PPE Strategies
por: Park, Jae Hyeon, et al.
Publicado: (2023) -
A Direct Rapid Phenotypic Antimicrobial Susceptibility Test Enables Early Selection of Optimal Antibiotics to Treat Bacteremia in COVID-19 Patients
por: Park, Do Hyeon, et al.
Publicado: (2021)